ESTRO 2025 - Abstract Book

S1431

Clinical - Lung

ESTRO 2025

Conclusion: SMARTER was feasible to deliver but resulted in poorer DFS compared to SMART. We hypothesize poorer outcomes were immune mediated. We have developed and currently accruing the next trial iteration, SMARTEST, to test the benefit of adding immunotherapy. Keywords: mesothelioma, multimodal therapy References: 1 Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A, Pal P, Cabanero M, Czarnecka K, McRae K, Tsao MS, de Perrot M. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021 Feb;22(2):190-197.

4206

Digital Poster Stereotactic body radiation therapy (SBRT) in patients affected by chronic obstructive pulmonary disease (COPD) and Non-Small Cell Lung Cancer (NSCLC) Jessica Saddi 1 , David Alberto Santos 2 , Elisabetta Bonzano 1 , Andrea Lancia 1 , Salvatore La Mattina 1 , Luigi Squillace 1 , Sara Colombo 1 , Laura Mantovani 3 , Anna Enrica Francia 3 , Monica Cavallari 3 , Gaetano Urso 3 , Paolo Pedrazzoli 4,5 1 Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 2 Radiation Oncology, National Istitute of Healt of Salvador, San Salvador, El Salvador. 3 Departement of Medical Physics, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 4 medical Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 5 Departement of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy